|
a |
|
b/html_files/28154281.html |
|
|
1 |
|
|
|
2 |
<!DOCTYPE html> |
|
|
3 |
<html> |
|
|
4 |
<head> |
|
|
5 |
<meta charset="utf-8"> |
|
|
6 |
<title>28154281 Visualization</title> |
|
|
7 |
</head> |
|
|
8 |
<body> |
|
|
9 |
<h1>28154281 Visualization</h1> |
|
|
10 |
<p><a href="main.html">Back to Main Page</a></p> |
|
|
11 |
<div class="entities" style="line-height: 2.5; direction: ltr">A |
|
|
12 |
<mark class="entity" style="background: #f6c3d0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
13 |
23 |
|
|
14 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Age</span> |
|
|
15 |
</mark> |
|
|
16 |
- |
|
|
17 |
<mark class="entity" style="background: #f6c3d0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
18 |
year |
|
|
19 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Age</span> |
|
|
20 |
</mark> |
|
|
21 |
- |
|
|
22 |
<mark class="entity" style="background: #f6c3d0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
23 |
old |
|
|
24 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Age</span> |
|
|
25 |
</mark> |
|
|
26 |
|
|
|
27 |
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
28 |
man |
|
|
29 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sex</span> |
|
|
30 |
</mark> |
|
|
31 |
with a history of |
|
|
32 |
<mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
33 |
severe |
|
|
34 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span> |
|
|
35 |
</mark> |
|
|
36 |
|
|
|
37 |
<mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
38 |
aplastic |
|
|
39 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span> |
|
|
40 |
</mark> |
|
|
41 |
|
|
|
42 |
<mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
43 |
anemia |
|
|
44 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span> |
|
|
45 |
</mark> |
|
|
46 |
( |
|
|
47 |
<mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
48 |
SAA |
|
|
49 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span> |
|
|
50 |
</mark> |
|
|
51 |
) underwent |
|
|
52 |
<mark class="entity" style="background: #e6ccb2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
53 |
bone |
|
|
54 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Therapeutic_procedure</span> |
|
|
55 |
</mark> |
|
|
56 |
|
|
|
57 |
<mark class="entity" style="background: #e6ccb2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
58 |
marrow |
|
|
59 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Therapeutic_procedure</span> |
|
|
60 |
</mark> |
|
|
61 |
|
|
|
62 |
<mark class="entity" style="background: #e6ccb2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
63 |
transplantation |
|
|
64 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Therapeutic_procedure</span> |
|
|
65 |
</mark> |
|
|
66 |
from his |
|
|
67 |
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
68 |
HLA |
|
|
69 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
|
|
70 |
</mark> |
|
|
71 |
- |
|
|
72 |
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
73 |
haploidentical |
|
|
74 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
|
|
75 |
</mark> |
|
|
76 |
|
|
|
77 |
<mark class="entity" style="background: #b9e8d8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
78 |
mother |
|
|
79 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Subject</span> |
|
|
80 |
</mark> |
|
|
81 |
in |
|
|
82 |
<mark class="entity" style="background: #f1f0d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
83 |
January |
|
|
84 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Date</span> |
|
|
85 |
</mark> |
|
|
86 |
|
|
|
87 |
<mark class="entity" style="background: #f1f0d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
88 |
2014 |
|
|
89 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Date</span> |
|
|
90 |
</mark> |
|
|
91 |
.</br>The conditioning regimens consisted of |
|
|
92 |
<mark class="entity" style="background: #f9d5e5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
93 |
busulphan |
|
|
94 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Medication</span> |
|
|
95 |
</mark> |
|
|
96 |
|
|
|
97 |
<mark class="entity" style="background: #f9d5e5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
98 |
cyclophosphamide |
|
|
99 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Medication</span> |
|
|
100 |
</mark> |
|
|
101 |
and |
|
|
102 |
<mark class="entity" style="background: #f9d5e5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
103 |
antithymocyte |
|
|
104 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Medication</span> |
|
|
105 |
</mark> |
|
|
106 |
|
|
|
107 |
<mark class="entity" style="background: #f9d5e5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
108 |
globulin |
|
|
109 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Medication</span> |
|
|
110 |
</mark> |
|
|
111 |
(BUCY+ATG) (10).</br> |
|
|
112 |
<mark class="entity" style="background: #f9d5e5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
113 |
Cyclosporine |
|
|
114 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Medication</span> |
|
|
115 |
</mark> |
|
|
116 |
|
|
|
117 |
<mark class="entity" style="background: #f9d5e5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
118 |
A |
|
|
119 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Medication</span> |
|
|
120 |
</mark> |
|
|
121 |
( |
|
|
122 |
<mark class="entity" style="background: #f9d5e5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
123 |
CsA |
|
|
124 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Medication</span> |
|
|
125 |
</mark> |
|
|
126 |
) and |
|
|
127 |
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
128 |
short |
|
|
129 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
|
|
130 |
</mark> |
|
|
131 |
- |
|
|
132 |
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
133 |
term |
|
|
134 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
|
|
135 |
</mark> |
|
|
136 |
|
|
|
137 |
<mark class="entity" style="background: #f9d5e5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
138 |
methotrexate |
|
|
139 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Medication</span> |
|
|
140 |
</mark> |
|
|
141 |
( |
|
|
142 |
<mark class="entity" style="background: #f9d5e5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
143 |
MTX |
|
|
144 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Medication</span> |
|
|
145 |
</mark> |
|
|
146 |
) plus |
|
|
147 |
<mark class="entity" style="background: #f9d5e5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
148 |
mycophenolate |
|
|
149 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Medication</span> |
|
|
150 |
</mark> |
|
|
151 |
|
|
|
152 |
<mark class="entity" style="background: #f9d5e5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
153 |
mofetil |
|
|
154 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Medication</span> |
|
|
155 |
</mark> |
|
|
156 |
( |
|
|
157 |
<mark class="entity" style="background: #f9d5e5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
158 |
MMF |
|
|
159 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Medication</span> |
|
|
160 |
</mark> |
|
|
161 |
) were used as prophylaxis against |
|
|
162 |
<mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
163 |
graft |
|
|
164 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span> |
|
|
165 |
</mark> |
|
|
166 |
- |
|
|
167 |
<mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
168 |
versus |
|
|
169 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span> |
|
|
170 |
</mark> |
|
|
171 |
- |
|
|
172 |
<mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
173 |
host |
|
|
174 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span> |
|
|
175 |
</mark> |
|
|
176 |
|
|
|
177 |
<mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
178 |
disease |
|
|
179 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span> |
|
|
180 |
</mark> |
|
|
181 |
( |
|
|
182 |
<mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
183 |
GVHD |
|
|
184 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span> |
|
|
185 |
</mark> |
|
|
186 |
) (11).</br>Standard measures were adopted for the prevention of |
|
|
187 |
<mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
188 |
infectious |
|
|
189 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span> |
|
|
190 |
</mark> |
|
|
191 |
|
|
|
192 |
<mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
193 |
complications |
|
|
194 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span> |
|
|
195 |
</mark> |
|
|
196 |
, which included |
|
|
197 |
<mark class="entity" style="background: #f9d5e5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
198 |
fluconazole |
|
|
199 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Medication</span> |
|
|
200 |
</mark> |
|
|
201 |
for |
|
|
202 |
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
203 |
antifungal |
|
|
204 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
|
|
205 |
</mark> |
|
|
206 |
|
|
|
207 |
<mark class="entity" style="background: #e6ccb2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
208 |
prophylaxis |
|
|
209 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Therapeutic_procedure</span> |
|
|
210 |
</mark> |
|
|
211 |
and |
|
|
212 |
<mark class="entity" style="background: #f9d5e5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
213 |
acyclovir |
|
|
214 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Medication</span> |
|
|
215 |
</mark> |
|
|
216 |
to prevent |
|
|
217 |
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
218 |
herpes |
|
|
219 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
|
|
220 |
</mark> |
|
|
221 |
- |
|
|
222 |
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
223 |
related |
|
|
224 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
|
|
225 |
</mark> |
|
|
226 |
|
|
|
227 |
<mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
228 |
infections |
|
|
229 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span> |
|
|
230 |
</mark> |
|
|
231 |
.</br>A |
|
|
232 |
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
233 |
hemogram |
|
|
234 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
|
|
235 |
</mark> |
|
|
236 |
revealed the |
|
|
237 |
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
238 |
reconstruction |
|
|
239 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span> |
|
|
240 |
</mark> |
|
|
241 |
|
|
|
242 |
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
243 |
of |
|
|
244 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span> |
|
|
245 |
</mark> |
|
|
246 |
|
|
|
247 |
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
248 |
granulocytes |
|
|
249 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span> |
|
|
250 |
</mark> |
|
|
251 |
(ANC>0.5×109/L) on |
|
|
252 |
<mark class="entity" style="background: #f1f0d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
253 |
day |
|
|
254 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Date</span> |
|
|
255 |
</mark> |
|
|
256 |
|
|
|
257 |
<mark class="entity" style="background: #f1f0d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
258 |
+12 |
|
|
259 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Date</span> |
|
|
260 |
</mark> |
|
|
261 |
post- |
|
|
262 |
<mark class="entity" style="background: #e6ccb2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
263 |
transplantation |
|
|
264 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Therapeutic_procedure</span> |
|
|
265 |
</mark> |
|
|
266 |
.</br>The patient developed |
|
|
267 |
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
268 |
grade |
|
|
269 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
|
|
270 |
</mark> |
|
|
271 |
|
|
|
272 |
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
273 |
II |
|
|
274 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
|
|
275 |
</mark> |
|
|
276 |
|
|
|
277 |
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
278 |
acute |
|
|
279 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
|
|
280 |
</mark> |
|
|
281 |
|
|
|
282 |
<mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
283 |
GVHD |
|
|
284 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span> |
|
|
285 |
</mark> |
|
|
286 |
of the |
|
|
287 |
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
288 |
skin |
|
|
289 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span> |
|
|
290 |
</mark> |
|
|
291 |
on |
|
|
292 |
<mark class="entity" style="background: #f1f0d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
293 |
day |
|
|
294 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Date</span> |
|
|
295 |
</mark> |
|
|
296 |
|
|
|
297 |
<mark class="entity" style="background: #f1f0d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
298 |
+42 |
|
|
299 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Date</span> |
|
|
300 |
</mark> |
|
|
301 |
post- |
|
|
302 |
<mark class="entity" style="background: #e6ccb2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
303 |
transplantation |
|
|
304 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Therapeutic_procedure</span> |
|
|
305 |
</mark> |
|
|
306 |
.</br>This was treated by treatment with a |
|
|
307 |
<mark class="entity" style="background: #b9e8d8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
308 |
standard |
|
|
309 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Dosage</span> |
|
|
310 |
</mark> |
|
|
311 |
- |
|
|
312 |
<mark class="entity" style="background: #b9e8d8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
313 |
dose |
|
|
314 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Dosage</span> |
|
|
315 |
</mark> |
|
|
316 |
of |
|
|
317 |
<mark class="entity" style="background: #f9d5e5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
318 |
methyl |
|
|
319 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Medication</span> |
|
|
320 |
</mark> |
|
|
321 |
- |
|
|
322 |
<mark class="entity" style="background: #f9d5e5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
323 |
prednisolone |
|
|
324 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Medication</span> |
|
|
325 |
</mark> |
|
|
326 |
, which achieved a |
|
|
327 |
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
328 |
complete |
|
|
329 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span> |
|
|
330 |
</mark> |
|
|
331 |
|
|
|
332 |
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
333 |
response |
|
|
334 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span> |
|
|
335 |
</mark> |
|
|
336 |
( |
|
|
337 |
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
338 |
CR |
|
|
339 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span> |
|
|
340 |
</mark> |
|
|
341 |
).</br>The patient's |
|
|
342 |
<mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
343 |
chronic |
|
|
344 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span> |
|
|
345 |
</mark> |
|
|
346 |
|
|
|
347 |
<mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
348 |
GVHD |
|
|
349 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span> |
|
|
350 |
</mark> |
|
|
351 |
( |
|
|
352 |
<mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
353 |
cGVHD |
|
|
354 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span> |
|
|
355 |
</mark> |
|
|
356 |
) of the |
|
|
357 |
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
358 |
skin |
|
|
359 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span> |
|
|
360 |
</mark> |
|
|
361 |
gradually progressed from |
|
|
362 |
<mark class="entity" style="background: #f1f0d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
363 |
day |
|
|
364 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Date</span> |
|
|
365 |
</mark> |
|
|
366 |
|
|
|
367 |
<mark class="entity" style="background: #f1f0d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
368 |
+100 |
|
|
369 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Date</span> |
|
|
370 |
</mark> |
|
|
371 |
post- |
|
|
372 |
<mark class="entity" style="background: #e6ccb2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
373 |
transplantation |
|
|
374 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Therapeutic_procedure</span> |
|
|
375 |
</mark> |
|
|
376 |
and he was treated with |
|
|
377 |
<mark class="entity" style="background: #f9d5e5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
378 |
prednisolone |
|
|
379 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Medication</span> |
|
|
380 |
</mark> |
|
|
381 |
and CsA.</br>On |
|
|
382 |
<mark class="entity" style="background: #f1f0d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
383 |
day |
|
|
384 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Date</span> |
|
|
385 |
</mark> |
|
|
386 |
|
|
|
387 |
<mark class="entity" style="background: #f1f0d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
388 |
120 |
|
|
389 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Date</span> |
|
|
390 |
</mark> |
|
|
391 |
post- |
|
|
392 |
<mark class="entity" style="background: #e6ccb2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
393 |
transplantation |
|
|
394 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Therapeutic_procedure</span> |
|
|
395 |
</mark> |
|
|
396 |
, he complained of a |
|
|
397 |
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
398 |
cough |
|
|
399 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span> |
|
|
400 |
</mark> |
|
|
401 |
and |
|
|
402 |
<mark class="entity" style="background: #f9d5e5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
403 |
antibiotics |
|
|
404 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Medication</span> |
|
|
405 |
</mark> |
|
|
406 |
were administered.</br>A |
|
|
407 |
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
408 |
blood |
|
|
409 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
|
|
410 |
</mark> |
|
|
411 |
|
|
|
412 |
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
413 |
analysis |
|
|
414 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
|
|
415 |
</mark> |
|
|
416 |
revealed the following: |
|
|
417 |
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
418 |
WBC |
|
|
419 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
|
|
420 |
</mark> |
|
|
421 |
, |
|
|
422 |
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
423 |
2.34×109/L |
|
|
424 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
|
|
425 |
</mark> |
|
|
426 |
; |
|
|
427 |
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
428 |
ANC |
|
|
429 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
|
|
430 |
</mark> |
|
|
431 |
, |
|
|
432 |
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
433 |
1.72×109/L |
|
|
434 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
|
|
435 |
</mark> |
|
|
436 |
; |
|
|
437 |
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
438 |
hemoglobin |
|
|
439 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
|
|
440 |
</mark> |
|
|
441 |
, |
|
|
442 |
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
443 |
85 |
|
|
444 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
|
|
445 |
</mark> |
|
|
446 |
|
|
|
447 |
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
448 |
g/L |
|
|
449 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
|
|
450 |
</mark> |
|
|
451 |
; and |
|
|
452 |
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
453 |
platelets |
|
|
454 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
|
|
455 |
</mark> |
|
|
456 |
, 72×109/L.</br>Although both a |
|
|
457 |
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
458 |
chest |
|
|
459 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span> |
|
|
460 |
</mark> |
|
|
461 |
|
|
|
462 |
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
463 |
computed |
|
|
464 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
|
|
465 |
</mark> |
|
|
466 |
|
|
|
467 |
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
468 |
tomography |
|
|
469 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
|
|
470 |
</mark> |
|
|
471 |
( |
|
|
472 |
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
473 |
CT |
|
|
474 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
|
|
475 |
</mark> |
|
|
476 |
) scan and |
|
|
477 |
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
478 |
tests |
|
|
479 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
|
|
480 |
</mark> |
|
|
481 |
|
|
|
482 |
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
483 |
for |
|
|
484 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
|
|
485 |
</mark> |
|
|
486 |
|
|
|
487 |
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
488 |
pathogens |
|
|
489 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
|
|
490 |
</mark> |
|
|
491 |
|
|
|
492 |
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
493 |
via |
|
|
494 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
|
|
495 |
</mark> |
|
|
496 |
|
|
|
497 |
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
498 |
routine |
|
|
499 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
|
|
500 |
</mark> |
|
|
501 |
|
|
|
502 |
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
503 |
culturing |
|
|
504 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
|
|
505 |
</mark> |
|
|
506 |
, including |
|
|
507 |
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
508 |
blood |
|
|
509 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
|
|
510 |
</mark> |
|
|
511 |
tests for |
|
|
512 |
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
513 |
Beta |
|
|
514 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
|
|
515 |
</mark> |
|
|
516 |
- |
|
|
517 |
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
518 |
D |
|
|
519 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
|
|
520 |
</mark> |
|
|
521 |
|
|
|
522 |
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
523 |
glucan |
|
|
524 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
|
|
525 |
</mark> |
|
|
526 |
( |
|
|
527 |
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
528 |
G |
|
|
529 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
|
|
530 |
</mark> |
|
|
531 |
- |
|
|
532 |
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
533 |
test |
|
|
534 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
|
|
535 |
</mark> |
|
|
536 |
) and |
|
|
537 |
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
538 |
Galactomannan |
|
|
539 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
|
|
540 |
</mark> |
|
|
541 |
( |
|
|
542 |
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
543 |
GM |
|
|
544 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
|
|
545 |
</mark> |
|
|
546 |
- |
|
|
547 |
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
548 |
test |
|
|
549 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
|
|
550 |
</mark> |
|
|
551 |
) were all |
|
|
552 |
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
553 |
negative |
|
|
554 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
|
|
555 |
</mark> |
|
|
556 |
, the patient's |
|
|
557 |
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
558 |
cough |
|
|
559 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span> |
|
|
560 |
</mark> |
|
|
561 |
did not respond to |
|
|
562 |
<mark class="entity" style="background: #f9d5e5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
563 |
antibiotics |
|
|
564 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Medication</span> |
|
|
565 |
</mark> |
|
|
566 |
and we empirically initiated treatment with |
|
|
567 |
<mark class="entity" style="background: #f9d5e5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
568 |
voriconazole |
|
|
569 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Medication</span> |
|
|
570 |
</mark> |
|
|
571 |
( |
|
|
572 |
<mark class="entity" style="background: #b9e8d8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
573 |
6 |
|
|
574 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Dosage</span> |
|
|
575 |
</mark> |
|
|
576 |
|
|
|
577 |
<mark class="entity" style="background: #b9e8d8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
578 |
mg/kg/12h |
|
|
579 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Dosage</span> |
|
|
580 |
</mark> |
|
|
581 |
|
|
|
582 |
<mark class="entity" style="background: #b9e8d8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
583 |
for |
|
|
584 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Dosage</span> |
|
|
585 |
</mark> |
|
|
586 |
|
|
|
587 |
<mark class="entity" style="background: #b9e8d8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
588 |
the |
|
|
589 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Dosage</span> |
|
|
590 |
</mark> |
|
|
591 |
|
|
|
592 |
<mark class="entity" style="background: #b9e8d8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
593 |
first |
|
|
594 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Dosage</span> |
|
|
595 |
</mark> |
|
|
596 |
|
|
|
597 |
<mark class="entity" style="background: #b9e8d8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
598 |
day |
|
|
599 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Dosage</span> |
|
|
600 |
</mark> |
|
|
601 |
, followed by |
|
|
602 |
<mark class="entity" style="background: #b9e8d8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
603 |
4 |
|
|
604 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Dosage</span> |
|
|
605 |
</mark> |
|
|
606 |
|
|
|
607 |
<mark class="entity" style="background: #b9e8d8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
608 |
mg/kg/12h |
|
|
609 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Dosage</span> |
|
|
610 |
</mark> |
|
|
611 |
).</br> |
|
|
612 |
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
613 |
Liver |
|
|
614 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span> |
|
|
615 |
</mark> |
|
|
616 |
|
|
|
617 |
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
618 |
toxicity |
|
|
619 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span> |
|
|
620 |
</mark> |
|
|
621 |
occurred during |
|
|
622 |
<mark class="entity" style="background: #f9d5e5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
623 |
voriconazole |
|
|
624 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Medication</span> |
|
|
625 |
</mark> |
|
|
626 |
treatment, thus the |
|
|
627 |
<mark class="entity" style="background: #e6ccb2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
628 |
anti |
|
|
629 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Therapeutic_procedure</span> |
|
|
630 |
</mark> |
|
|
631 |
- |
|
|
632 |
<mark class="entity" style="background: #e6ccb2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
633 |
fungal |
|
|
634 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Therapeutic_procedure</span> |
|
|
635 |
</mark> |
|
|
636 |
|
|
|
637 |
<mark class="entity" style="background: #e6ccb2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
638 |
regimen |
|
|
639 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Therapeutic_procedure</span> |
|
|
640 |
</mark> |
|
|
641 |
was changed to |
|
|
642 |
<mark class="entity" style="background: #f9d5e5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
643 |
micafungin |
|
|
644 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Medication</span> |
|
|
645 |
</mark> |
|
|
646 |
( |
|
|
647 |
<mark class="entity" style="background: #b9e8d8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
648 |
100 |
|
|
649 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Dosage</span> |
|
|
650 |
</mark> |
|
|
651 |
|
|
|
652 |
<mark class="entity" style="background: #b9e8d8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
653 |
mg/d |
|
|
654 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Dosage</span> |
|
|
655 |
</mark> |
|
|
656 |
).</br>However, the |
|
|
657 |
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
658 |
persistent |
|
|
659 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
|
|
660 |
</mark> |
|
|
661 |
|
|
|
662 |
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
663 |
cough |
|
|
664 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span> |
|
|
665 |
</mark> |
|
|
666 |
did not improve and |
|
|
667 |
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
668 |
hoarseness |
|
|
669 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span> |
|
|
670 |
</mark> |
|
|
671 |
developed |
|
|
672 |
<mark class="entity" style="background: #f1f0d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
673 |
after |
|
|
674 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Date</span> |
|
|
675 |
</mark> |
|
|
676 |
|
|
|
677 |
<mark class="entity" style="background: #f1f0d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
678 |
two |
|
|
679 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Date</span> |
|
|
680 |
</mark> |
|
|
681 |
|
|
|
682 |
<mark class="entity" style="background: #f1f0d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
683 |
weeks |
|
|
684 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Date</span> |
|
|
685 |
</mark> |
|
|
686 |
of treatment - |
|
|
687 |
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
688 |
ulcers |
|
|
689 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span> |
|
|
690 |
</mark> |
|
|
691 |
were then observed in the |
|
|
692 |
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
693 |
throat |
|
|
694 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span> |
|
|
695 |
</mark> |
|
|
696 |
by |
|
|
697 |
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
698 |
laryngoscopy |
|
|
699 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
|
|
700 |
</mark> |
|
|
701 |
(Fig.1a).</br>The patient developed |
|
|
702 |
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
703 |
severe |
|
|
704 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Severity</span> |
|
|
705 |
</mark> |
|
|
706 |
|
|
|
707 |
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
708 |
dyspnea |
|
|
709 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span> |
|
|
710 |
</mark> |
|
|
711 |
|
|
|
712 |
<mark class="entity" style="background: #f1f0d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
713 |
in |
|
|
714 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Date</span> |
|
|
715 |
</mark> |
|
|
716 |
|
|
|
717 |
<mark class="entity" style="background: #f1f0d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
718 |
the |
|
|
719 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Date</span> |
|
|
720 |
</mark> |
|
|
721 |
|
|
|
722 |
<mark class="entity" style="background: #f1f0d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
723 |
following |
|
|
724 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Date</span> |
|
|
725 |
</mark> |
|
|
726 |
|
|
|
727 |
<mark class="entity" style="background: #f1f0d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
728 |
week |
|
|
729 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Date</span> |
|
|
730 |
</mark> |
|
|
731 |
when |
|
|
732 |
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
733 |
anti |
|
|
734 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
|
|
735 |
</mark> |
|
|
736 |
- |
|
|
737 |
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
738 |
infection |
|
|
739 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
|
|
740 |
</mark> |
|
|
741 |
and |
|
|
742 |
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
743 |
topical |
|
|
744 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
|
|
745 |
</mark> |
|
|
746 |
|
|
|
747 |
<mark class="entity" style="background: #e6ccb2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
748 |
treatments |
|
|
749 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Therapeutic_procedure</span> |
|
|
750 |
</mark> |
|
|
751 |
were applied.</br> |
|
|
752 |
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
753 |
Fiberoptic |
|
|
754 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
|
|
755 |
</mark> |
|
|
756 |
|
|
|
757 |
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
758 |
bronchoscopy |
|
|
759 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
|
|
760 |
</mark> |
|
|
761 |
revealed an |
|
|
762 |
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
763 |
irregular |
|
|
764 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
|
|
765 |
</mark> |
|
|
766 |
, |
|
|
767 |
<mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
768 |
nodular |
|
|
769 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Shape</span> |
|
|
770 |
</mark> |
|
|
771 |
|
|
|
772 |
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
773 |
material |
|
|
774 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span> |
|
|
775 |
</mark> |
|
|
776 |
with |
|
|
777 |
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
778 |
white |
|
|
779 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
|
|
780 |
</mark> |
|
|
781 |
|
|
|
782 |
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
783 |
moss |
|
|
784 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
|
|
785 |
</mark> |
|
|
786 |
, which |
|
|
787 |
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
788 |
nearly |
|
|
789 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
|
|
790 |
</mark> |
|
|
791 |
|
|
|
792 |
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
793 |
obstructed |
|
|
794 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span> |
|
|
795 |
</mark> |
|
|
796 |
the |
|
|
797 |
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
798 |
bronchus |
|
|
799 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span> |
|
|
800 |
</mark> |
|
|
801 |
; however, |
|
|
802 |
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
803 |
chest |
|
|
804 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span> |
|
|
805 |
</mark> |
|
|
806 |
|
|
|
807 |
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
808 |
CT |
|
|
809 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
|
|
810 |
</mark> |
|
|
811 |
imaging was |
|
|
812 |
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
813 |
negative |
|
|
814 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
|
|
815 |
</mark> |
|
|
816 |
(Fig.1b and c).</br>The |
|
|
817 |
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
818 |
histopathological |
|
|
819 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
|
|
820 |
</mark> |
|
|
821 |
|
|
|
822 |
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
823 |
examination |
|
|
824 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
|
|
825 |
</mark> |
|
|
826 |
of |
|
|
827 |
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
828 |
biopsy |
|
|
829 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
|
|
830 |
</mark> |
|
|
831 |
specimens revealed an |
|
|
832 |
<mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
833 |
Aspergillus |
|
|
834 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span> |
|
|
835 |
</mark> |
|
|
836 |
species (Fig.1d).</br>The patient was diagnosed with |
|
|
837 |
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
838 |
pseudomembranous |
|
|
839 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
|
|
840 |
</mark> |
|
|
841 |
|
|
|
842 |
<mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
843 |
Aspergillus |
|
|
844 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span> |
|
|
845 |
</mark> |
|
|
846 |
|
|
|
847 |
<mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
848 |
tracheobronchitis |
|
|
849 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span> |
|
|
850 |
</mark> |
|
|
851 |
|
|
|
852 |
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
853 |
type |
|
|
854 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
|
|
855 |
</mark> |
|
|
856 |
|
|
|
857 |
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
858 |
ITBA |
|
|
859 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
|
|
860 |
</mark> |
|
|
861 |
based on the results of |
|
|
862 |
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
863 |
bronchoscopy |
|
|
864 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
|
|
865 |
</mark> |
|
|
866 |
and a |
|
|
867 |
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
868 |
pathological |
|
|
869 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
|
|
870 |
</mark> |
|
|
871 |
|
|
|
872 |
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
873 |
examination |
|
|
874 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
|
|
875 |
</mark> |
|
|
876 |
(12).</br>The |
|
|
877 |
<mark class="entity" style="background: #f9d5e5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
878 |
antibiotic |
|
|
879 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Medication</span> |
|
|
880 |
</mark> |
|
|
881 |
and |
|
|
882 |
<mark class="entity" style="background: #f9d5e5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
883 |
micafungin |
|
|
884 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Medication</span> |
|
|
885 |
</mark> |
|
|
886 |
treatments were ceased and |
|
|
887 |
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
888 |
liposomal |
|
|
889 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
|
|
890 |
</mark> |
|
|
891 |
|
|
|
892 |
<mark class="entity" style="background: #f9d5e5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
893 |
amphotericin |
|
|
894 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Medication</span> |
|
|
895 |
</mark> |
|
|
896 |
|
|
|
897 |
<mark class="entity" style="background: #f9d5e5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
898 |
B |
|
|
899 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Medication</span> |
|
|
900 |
</mark> |
|
|
901 |
( |
|
|
902 |
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
903 |
liposomal |
|
|
904 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
|
|
905 |
</mark> |
|
|
906 |
|
|
|
907 |
<mark class="entity" style="background: #f9d5e5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
908 |
AmB |
|
|
909 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Medication</span> |
|
|
910 |
</mark> |
|
|
911 |
) was administered |
|
|
912 |
<mark class="entity" style="background: #b9e8d8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
913 |
daily |
|
|
914 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Dosage</span> |
|
|
915 |
</mark> |
|
|
916 |
at a target dose of |
|
|
917 |
<mark class="entity" style="background: #b9e8d8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
918 |
3 |
|
|
919 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Dosage</span> |
|
|
920 |
</mark> |
|
|
921 |
|
|
|
922 |
<mark class="entity" style="background: #b9e8d8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
923 |
mg/kg |
|
|
924 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Dosage</span> |
|
|
925 |
</mark> |
|
|
926 |
.</br>The patient's |
|
|
927 |
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
928 |
serum |
|
|
929 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
|
|
930 |
</mark> |
|
|
931 |
|
|
|
932 |
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
933 |
creatinine |
|
|
934 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
|
|
935 |
</mark> |
|
|
936 |
level |
|
|
937 |
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
938 |
rose |
|
|
939 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
|
|
940 |
</mark> |
|
|
941 |
from |
|
|
942 |
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
943 |
60.4 |
|
|
944 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
|
|
945 |
</mark> |
|
|
946 |
|
|
|
947 |
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
948 |
μmol/L |
|
|
949 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
|
|
950 |
</mark> |
|
|
951 |
to |
|
|
952 |
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
953 |
168 |
|
|
954 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
|
|
955 |
</mark> |
|
|
956 |
|
|
|
957 |
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
958 |
μmol/L |
|
|
959 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
|
|
960 |
</mark> |
|
|
961 |
|
|
|
962 |
<mark class="entity" style="background: #f1f0d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
963 |
during |
|
|
964 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Date</span> |
|
|
965 |
</mark> |
|
|
966 |
|
|
|
967 |
<mark class="entity" style="background: #f1f0d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
968 |
the |
|
|
969 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Date</span> |
|
|
970 |
</mark> |
|
|
971 |
|
|
|
972 |
<mark class="entity" style="background: #f1f0d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
973 |
first |
|
|
974 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Date</span> |
|
|
975 |
</mark> |
|
|
976 |
|
|
|
977 |
<mark class="entity" style="background: #f1f0d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
978 |
7 |
|
|
979 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Date</span> |
|
|
980 |
</mark> |
|
|
981 |
|
|
|
982 |
<mark class="entity" style="background: #f1f0d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
983 |
days |
|
|
984 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Date</span> |
|
|
985 |
</mark> |
|
|
986 |
of |
|
|
987 |
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
988 |
liposomal |
|
|
989 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
|
|
990 |
</mark> |
|
|
991 |
|
|
|
992 |
<mark class="entity" style="background: #f9d5e5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
993 |
AmB |
|
|
994 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Medication</span> |
|
|
995 |
</mark> |
|
|
996 |
treatment.</br>Due to |
|
|
997 |
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
998 |
progressive |
|
|
999 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Severity</span> |
|
|
1000 |
</mark> |
|
|
1001 |
|
|
|
1002 |
<mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
1003 |
renal |
|
|
1004 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span> |
|
|
1005 |
</mark> |
|
|
1006 |
|
|
|
1007 |
<mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
1008 |
dysfunction |
|
|
1009 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span> |
|
|
1010 |
</mark> |
|
|
1011 |
, the |
|
|
1012 |
<mark class="entity" style="background: #f9d5e5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
1013 |
anti |
|
|
1014 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Medication</span> |
|
|
1015 |
</mark> |
|
|
1016 |
- |
|
|
1017 |
<mark class="entity" style="background: #f9d5e5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
1018 |
fungal |
|
|
1019 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Medication</span> |
|
|
1020 |
</mark> |
|
|
1021 |
regimen was switched to a combination of |
|
|
1022 |
<mark class="entity" style="background: #f9d5e5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
1023 |
posaconazole |
|
|
1024 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Medication</span> |
|
|
1025 |
</mark> |
|
|
1026 |
( |
|
|
1027 |
<mark class="entity" style="background: #b9e8d8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
1028 |
400 |
|
|
1029 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Dosage</span> |
|
|
1030 |
</mark> |
|
|
1031 |
|
|
|
1032 |
<mark class="entity" style="background: #b9e8d8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
1033 |
mg/12 |
|
|
1034 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Dosage</span> |
|
|
1035 |
</mark> |
|
|
1036 |
|
|
|
1037 |
<mark class="entity" style="background: #b9e8d8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
1038 |
h |
|
|
1039 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Dosage</span> |
|
|
1040 |
</mark> |
|
|
1041 |
) and |
|
|
1042 |
<mark class="entity" style="background: #f9d5e5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
1043 |
caspofungin |
|
|
1044 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Medication</span> |
|
|
1045 |
</mark> |
|
|
1046 |
[ |
|
|
1047 |
<mark class="entity" style="background: #b9e8d8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
1048 |
50 |
|
|
1049 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Dosage</span> |
|
|
1050 |
</mark> |
|
|
1051 |
|
|
|
1052 |
<mark class="entity" style="background: #b9e8d8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
1053 |
mg, |
|
|
1054 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Dosage</span> |
|
|
1055 |
</mark> |
|
|
1056 |
|
|
|
1057 |
<mark class="entity" style="background: #b9e8d8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
1058 |
daily |
|
|
1059 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Dosage</span> |
|
|
1060 |
</mark> |
|
|
1061 |
( |
|
|
1062 |
<mark class="entity" style="background: #b9e8d8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
1063 |
70 |
|
|
1064 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Dosage</span> |
|
|
1065 |
</mark> |
|
|
1066 |
|
|
|
1067 |
<mark class="entity" style="background: #b9e8d8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
1068 |
mg |
|
|
1069 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Dosage</span> |
|
|
1070 |
</mark> |
|
|
1071 |
|
|
|
1072 |
<mark class="entity" style="background: #b9e8d8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
1073 |
for |
|
|
1074 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Dosage</span> |
|
|
1075 |
</mark> |
|
|
1076 |
|
|
|
1077 |
<mark class="entity" style="background: #b9e8d8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
1078 |
the |
|
|
1079 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Dosage</span> |
|
|
1080 |
</mark> |
|
|
1081 |
|
|
|
1082 |
<mark class="entity" style="background: #b9e8d8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
1083 |
first |
|
|
1084 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Dosage</span> |
|
|
1085 |
</mark> |
|
|
1086 |
|
|
|
1087 |
<mark class="entity" style="background: #b9e8d8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
1088 |
dose |
|
|
1089 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Dosage</span> |
|
|
1090 |
</mark> |
|
|
1091 |
)].</br>The |
|
|
1092 |
<mark class="entity" style="background: #f9d5e5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
1093 |
combination |
|
|
1094 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Medication</span> |
|
|
1095 |
</mark> |
|
|
1096 |
|
|
|
1097 |
<mark class="entity" style="background: #f9d5e5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
1098 |
therapy |
|
|
1099 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Medication</span> |
|
|
1100 |
</mark> |
|
|
1101 |
continued for |
|
|
1102 |
<mark class="entity" style="background: #ffdfba; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
1103 |
2 |
|
|
1104 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Duration</span> |
|
|
1105 |
</mark> |
|
|
1106 |
|
|
|
1107 |
<mark class="entity" style="background: #ffdfba; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
1108 |
weeks |
|
|
1109 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Duration</span> |
|
|
1110 |
</mark> |
|
|
1111 |
, until the previous |
|
|
1112 |
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
1113 |
nodules |
|
|
1114 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span> |
|
|
1115 |
</mark> |
|
|
1116 |
in the |
|
|
1117 |
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
1118 |
throat |
|
|
1119 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span> |
|
|
1120 |
</mark> |
|
|
1121 |
completely disappeared under |
|
|
1122 |
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
1123 |
bronchoscopy |
|
|
1124 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
|
|
1125 |
</mark> |
|
|
1126 |
(Fig.2a); however, a repeat |
|
|
1127 |
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
1128 |
chest |
|
|
1129 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span> |
|
|
1130 |
</mark> |
|
|
1131 |
|
|
|
1132 |
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
1133 |
CT |
|
|
1134 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
|
|
1135 |
</mark> |
|
|
1136 |
scan showed |
|
|
1137 |
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
1138 |
progression |
|
|
1139 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span> |
|
|
1140 |
</mark> |
|
|
1141 |
(Fig.2b).</br>The symptom of |
|
|
1142 |
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
1143 |
dyspnea |
|
|
1144 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span> |
|
|
1145 |
</mark> |
|
|
1146 |
gradually progressed, thus |
|
|
1147 |
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
1148 |
fiberoptic |
|
|
1149 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
|
|
1150 |
</mark> |
|
|
1151 |
|
|
|
1152 |
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
1153 |
bronchoscopy |
|
|
1154 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
|
|
1155 |
</mark> |
|
|
1156 |
was performed to |
|
|
1157 |
<mark class="entity" style="background: #e6ccb2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
1158 |
remove |
|
|
1159 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Therapeutic_procedure</span> |
|
|
1160 |
</mark> |
|
|
1161 |
the |
|
|
1162 |
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
1163 |
obstructive |
|
|
1164 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span> |
|
|
1165 |
</mark> |
|
|
1166 |
|
|
|
1167 |
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
1168 |
material |
|
|
1169 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span> |
|
|
1170 |
</mark> |
|
|
1171 |
from the patient's |
|
|
1172 |
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
1173 |
airways |
|
|
1174 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span> |
|
|
1175 |
</mark> |
|
|
1176 |
|
|
|
1177 |
<mark class="entity" style="background: #e9d8a6; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
1178 |
once |
|
|
1179 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Frequency</span> |
|
|
1180 |
</mark> |
|
|
1181 |
|
|
|
1182 |
<mark class="entity" style="background: #e9d8a6; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
1183 |
a |
|
|
1184 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Frequency</span> |
|
|
1185 |
</mark> |
|
|
1186 |
|
|
|
1187 |
<mark class="entity" style="background: #e9d8a6; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
1188 |
week |
|
|
1189 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Frequency</span> |
|
|
1190 |
</mark> |
|
|
1191 |
for |
|
|
1192 |
<mark class="entity" style="background: #ffdfba; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
1193 |
two |
|
|
1194 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Duration</span> |
|
|
1195 |
</mark> |
|
|
1196 |
|
|
|
1197 |
<mark class="entity" style="background: #ffdfba; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
1198 |
weeks |
|
|
1199 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Duration</span> |
|
|
1200 |
</mark> |
|
|
1201 |
.</br>All of the |
|
|
1202 |
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
1203 |
symptoms |
|
|
1204 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span> |
|
|
1205 |
</mark> |
|
|
1206 |
were relieved and the final |
|
|
1207 |
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
1208 |
chest |
|
|
1209 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span> |
|
|
1210 |
</mark> |
|
|
1211 |
|
|
|
1212 |
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
1213 |
CT |
|
|
1214 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
|
|
1215 |
</mark> |
|
|
1216 |
scan showed |
|
|
1217 |
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
1218 |
negative |
|
|
1219 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
|
|
1220 |
</mark> |
|
|
1221 |
results before the discontinuation of |
|
|
1222 |
<mark class="entity" style="background: #f9d5e5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
1223 |
anti |
|
|
1224 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Medication</span> |
|
|
1225 |
</mark> |
|
|
1226 |
- |
|
|
1227 |
<mark class="entity" style="background: #f9d5e5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
1228 |
fungal |
|
|
1229 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Medication</span> |
|
|
1230 |
</mark> |
|
|
1231 |
therapy, and all of the |
|
|
1232 |
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
1233 |
tests |
|
|
1234 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
|
|
1235 |
</mark> |
|
|
1236 |
were |
|
|
1237 |
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
1238 |
negative |
|
|
1239 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
|
|
1240 |
</mark> |
|
|
1241 |
for |
|
|
1242 |
<mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
1243 |
Aspergillus |
|
|
1244 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span> |
|
|
1245 |
</mark> |
|
|
1246 |
.</br> |
|
|
1247 |
<mark class="entity" style="background: #f9d5e5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
1248 |
Posaconazole |
|
|
1249 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Medication</span> |
|
|
1250 |
</mark> |
|
|
1251 |
was administered as a secondary |
|
|
1252 |
<mark class="entity" style="background: #e6ccb2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
1253 |
prophylactic |
|
|
1254 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Therapeutic_procedure</span> |
|
|
1255 |
</mark> |
|
|
1256 |
|
|
|
1257 |
<mark class="entity" style="background: #e6ccb2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
1258 |
treatment |
|
|
1259 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Therapeutic_procedure</span> |
|
|
1260 |
</mark> |
|
|
1261 |
and the patient was |
|
|
1262 |
<mark class="entity" style="background: #77c5d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
1263 |
discharged |
|
|
1264 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Clinical_event</span> |
|
|
1265 |
</mark> |
|
|
1266 |
from |
|
|
1267 |
<mark class="entity" style="background: #f7a399; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
1268 |
hospital |
|
|
1269 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Nonbiological_location</span> |
|
|
1270 |
</mark> |
|
|
1271 |
.</br>The patient is still being |
|
|
1272 |
<mark class="entity" style="background: #77c5d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
1273 |
followed |
|
|
1274 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Clinical_event</span> |
|
|
1275 |
</mark> |
|
|
1276 |
and remains free of any recurrence of |
|
|
1277 |
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
1278 |
invasive |
|
|
1279 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
|
|
1280 |
</mark> |
|
|
1281 |
|
|
|
1282 |
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
1283 |
fungal |
|
|
1284 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
|
|
1285 |
</mark> |
|
|
1286 |
|
|
|
1287 |
<mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
1288 |
infection |
|
|
1289 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span> |
|
|
1290 |
</mark> |
|
|
1291 |
.</br></div> |
|
|
1292 |
</body> |
|
|
1293 |
</html> |
|
|
1294 |
|